DIANT® Pharma, Inc., established in 2019, has introduced cutting-edge, end-to-end manufacturing platforms distinguished by its adaptability and seamlessly integrating nanoparticle generation with all downstream operations as a closed system. This innovative framework delivers a multitude of advantages, including a more compact production footprint, decreased facility requirements, heightened scalability, reduced human intervention, elimination of holding intervals, and precise regulation over particle size distribution.

DIANT’s innovative blueprint for continuous nanoparticle production is predicated on an end-to-end manufacturing platform tailored for nucleic acid–LNPs, placing an emphasis on a closed-loop system design and exhaustive process monitoring protocols. The proprietary DIANT® Jet technology serves as the linchpin for efficient LNP generation through controlled mixing methodologies, ensuring the production of LNPs featuring unwavering uniformity, scalability across diverse applications, and exceptional particle characteristics.